Cipla: Cipla's Goa API facility receives VAI status from USFDA
Cipla announced that its wholly-owned subsidiary, Medispray Laboratories, has received a voluntary action indicated (VAI) classification from the U.S. Food and Drug Administration (USFDA) for its API manufacturing facility located in Goa.
Read full article »
Cipla develops and produces drugs for the treatment of arthritis, diabetes, weight control, depression and cardiovascular diseases.
Read more